Trends in Surgical Research in Head and Neck Cancer
- 279 Downloads
The task of surgical research is to improve the efficacy of available surgical therapeutic modalities, develop new ones, and balance this well with favorable functional outcome. Therefore, surgical research is composed of a translational and a clinical component. In translational surgical research, animal models are used to better understand the biology of head and neck cancers, but even more importantly, the biology of changes to the disease and the microenvironment created by surgical interventions. Animal models additionally allow for the development of image-guided surgery systems, novel strategies of intraoperative adjuvant treatment, and patient “avatars” to test innovative anticancer drug combinations. In clinical surgical research, surgical techniques are validated in clinical trials for effectiveness of tumor control and improvement of functional recovery of the patient. In conclusion, surgical research for head and neck cancer is an active field spanning across the entire breadth of basic and clinical science devoted to a better understanding of what surgery does to the disease and to the patient.
KeywordsHead and neck cancer HNSCC Animal models Clinical trials Translational research
We thank the Swiss National Science Foundation (SNF 310030L_144267 and 310030_152875) for the financial support.
Compliance with Ethical Standards
Conflict of Interest
The authors declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
Although this article refers to previously conducted studies with human and/or animal subjects performed by the authors, no new studies were conducted for this particular article.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.• Behren A, Kamenisch Y, Muehlen S, Flechtenmacher C, Haberkorn U, Hilber H, et al. Development of an oral cancer recurrence mouse model after surgical resection. Int J Oncol. 2010;36(4):849–55. This report presents the first mouse model of oral post-surgical tumor recurrence.Google Scholar
- 5.• Atallah I, Milet C, Henry M, Josserand V, Reyt E, Coll JL, et al. Near-infrared fluorescence imaging-guided surgery improves recurrence-free survival rate in novel orthotopic animal model of head and neck squamous cell carcinoma. Head & neck. 2016;38(Suppl 1):E246–55. doi: 10.1002/hed.23980. This study describes a new surgical xenograft mouse model based on HNSCC tumor piece implantation into the cheek and the application of the AngioStamp 800 NIR fluorescent probe for image-guided resection.
- 6.•• Kerk S, Finkel K, Pearson AT, Warner K, Nor F, Zhang Z, et al. 5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016; doi: 10.1158/1078-0432.CCR-16-1834. In this publication, Kerk and colleagues demonstrated a recurrence-preventive effect of neoadjuvantly administrated MEDI0641 antibody-drug conjugate in surgical HNSCC PDX models. MEDI0641, an anti-trophoblast glycoprotein (5T4 antigen) antibody, which carries pyrrolobenzodiazepine as a “payload”, a highly cytotoxic, sequence-selective DNA minor-groove binding agent with a crosslinking activity, efficiently depletes CSCs, a tumor cell fraction with an anticipated contribution to the origin of post-surgical local recurrences.
- 10.Owen JH, Graham MP, Chinn SB, Darr OF, Chepeha DB, Wolf GT, et al. Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head & neck. 2016;38(Suppl 1):E459–67. doi: 10.1002/hed.24019.CrossRefGoogle Scholar
- 12.Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingelhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Archives of otolaryngology--head & neck surgery. 2007;133(5):495–502. doi: 10.1001/archotol.133.5.495.CrossRefGoogle Scholar
- 25.• Iqbal H, Pan Q. Image guided surgery in the management of head and neck cancer. Oral Oncol. 2016;57:32–9. doi: 10.1016/j.oraloncology.2016.04.007. This article reviews the current state of intraoperative fluorescent imaging reagents and technologies in head and neck cancer image-guided surgery.
- 27.van Driel PB, van der Vorst JR, Verbeek FP, Oliveira S, Snoeks TJ, Keereweer S, et al. Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody. International journal of cancer Journal international du cancer. 2014;134(11):2663–73. doi: 10.1002/ijc.28601.CrossRefPubMedGoogle Scholar
- 28.• Heath CH, Deep NL, Sweeny L, Zinn KR, Rosenthal EL. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol. 2012;19(12):3879–87. doi: 10.1245/s10434-012-2435-y. This pre-clinical study demonstrates advantages of Panitumumab, a fully humanized EGFR antibody, conjugated with a NIR fluorescent dye IRDye800CW for image-guided surgery using an FDA-approved intraoperative imaging system and for the detection of microscopic residual disease in tissue specimens.
- 29.•• Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, et al. Safety and tumor specificity of Cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(16):3658–66. doi: 10.1158/1078-0432.CCR-14-3284. In this article, Rosenthal and colleagues describe a first in-human dose escalation study in a small cohort of HNSCC patients using intravenous administration of a cetuximab-IRDye800 conjugate. A combination of wide-field and closed-field NIR imaging systems for intraoperative, real-time delineation of tumor margins and ex vivo analysis of freshly-processed tissue sections using the fluorescently labeled, tumor cell specific therapeutic antibodies holds great promise for routine clinical application to increase the precision of surgical procedure preventing over- or under-resections.
- 30.•• de Boer E, Warram JM, Tucker MD, Hartman YE, Moore LS, de Jong JS, et al. In vivo fluorescence immunohistochemistry: localization of fluorescently labeled Cetuximab in squamous cell carcinomas. Scientific reports. 2015;5:10169. doi: 10.1038/srep10169. In the first in-human study of a systemically administered cetuximab-IRDye800CW conjugate, de Boer and colleagues established an in vivo fluorescence immunohistochemistry, an intraoperative fluorescence guided analysis of frozen sections, to help surgeons to accurately delineate the border between head and neck tumor and adjacent normal tissue.
- 31.• Muhanna N, Cui L, Chan H, Burgess L, Jin CS, MacDonald TD, et al. Multimodal image-guided surgical and photodynamic interventions in head and neck cancer: from primary tumor to metastatic drainage. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22(4):961–70. doi: 10.1158/1078-0432.CCR-15-1235. In this study, biocompatible copper-64 labeled porphyrin lipoprotein-mimicking nanoparticles were successfully tested for PET, intraoperative fluorescence imaging and laser light-induced photodynamic anti-tumor intervention in a pre-clinical model of rabbit buccal cavity cancer demonstrating no toxicity and high efficiency as imaging and therapeutic agents.
- 33.Ahn PH, Quon H, O'Malley BW, Weinstein G, Chalian A, Malloy K, et al. Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors. Oral Oncol. 2016;55:37–42. doi: 10.1016/j.oraloncology.2016.01.013.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, et al. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option. International journal of cancer Journal international du cancer. 2015;136(12):2940–8. doi: 10.1002/ijc.29344.CrossRefPubMedGoogle Scholar
- 36.Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, et al. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med. 2013;11:198. doi: 10.1186/1479-5876-11-198.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.•• Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, et al. XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene. 2016;35(3):290–300. doi: 10.1038/onc.2015.94. In this publication, Morton and colleagues presented a revolutionary approach for generation of HNSCC PDX-engrafted mice (XactMice) by reconstitution of human immune system and tumor stromal compartment using ex vivo expanded, cord blood-derived human hematopoietic stem and progenitor cells (HSPCs). In this humanized NSGTM mice, human cells originating in the engrafted bone marrow express CD45, a human hematopoietic cell surface marker of B-cells, T- cells, and hematopoietic progenitors, and CD151, a mesenchymal cell associated protein, and contribute to the development of stroma and lymphoangiogenesis in PDX tumors.
- 43.Lott DG, Russell JO, Khariwala SS, Dan O, Strome M. Ten-month laryngeal allograft survival with use of pulsed everolimus and anti-alphabeta T-cell receptor antibody immunosuppression. The Annals of otology, rhinology, and laryngology. 2011;120(2):131–6. doi: 10.1177/000348941112000210.CrossRefPubMedGoogle Scholar
- 52.Devaiah A, Murchison C. Analysis of 473 US head and neck cancer trials (1996-2014): trends, gaps, and opportunities. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2016;154(2):309–14. doi: 10.1177/0194599815617723.CrossRefGoogle Scholar
- 54.Schmitz S, Hamoir M, Reychler H, Magremanne M, Weynand B, Lhommel R, et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology. 2013;24(9):2261–6. doi: 10.1093/annonc/mdt180.CrossRefGoogle Scholar
- 55.Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(23):7086–92. doi: 10.1158/1078-0432.ccr-07-1370.CrossRefGoogle Scholar
- 56.Del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, Bourhis J, et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2011;105(5):618–27. doi: 10.1038/bjc.2011.237.CrossRefPubMedPubMedCentralGoogle Scholar
- 57.Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, et al. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20(12):3289–98. doi: 10.1158/1078-0432.ccr-13-3360.CrossRefGoogle Scholar
- 58.• Glass GE, Mosahebi A, Shakib K. Cross-specialty developments: a summary of the mutually relevant recent literature from the journal of plastic, reconstructive and aesthetic surgery. Br J Oral Maxillofac Surg. 2016;54(1):13–21. doi: 10.1016/j.bjoms.2015.08.272. This review summarizes recent publications in the field of head and neck and facial reconstructive and aesthetic surgery including flap techniques after oncologic surgery.
- 59.• Miller MQ, Dighe A, Cui Q, Park SS, Christophel JJ. Regenerative medicine in facial plastic and reconstructive surgery: a review. JAMA facial plastic surgery. 2016;18(5):391–4. doi: 10.1001/jamafacial.2016.0913. This recent review summarizes advances in facial plastic and reconstructive surgery including the application of stem cells, growth factors, platelet-rich plasma, and synthetic scaffolds.
- 60.• Markey J, Knott PD, Fritz MA, Seth R. Recent advances in head and neck free tissue transfer. Current opinion in otolaryngology & head and neck surgery. 2015;23(4):297–301. doi: 10.1097/MOO.0000000000000169. This article discusses recent progress in techniques of head and neck free tissue transfer.
- 61.• Ward MC, Koyfman SA. Transoral robotic surgery: the radiation oncologist’s perspective. Oral Oncol. 2016;60:96–102. doi: 10.1016/j.oraloncology.2016.07.008. This review article discusses current issues and open questions in the integration of TORS with IMRT and optimal selection of patients who will most likely benefit from the single or combination modalities.
- 65.•• Holsinger FC, Ferris RL. Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: robotics, lasers, and clinical trials. J Clin Oncol. 2015;33(29):3285–92. doi: 10.1200/JCO.2015.62.3157. This article reviews recent technological advances in transoral endoscopic head and neck surgery and discusses ongoing clinical trials aiming to evaluate the selection of TORS as a primary treatment modality for patients with oropharyngeal cancer.
- 66.Owadally W, Hurt C, Timmins H, Parsons E, Townsend S, Patterson J, et al. PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer. 2015;15:602. doi: 10.1186/s12885-015-1598-x.CrossRefPubMedPubMedCentralGoogle Scholar
- 67.Nichols AC, Yoo J, Hammond JA, Fung K, Winquist E, Read N, et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR)—study protocol for a randomized phase II trial. BMC Cancer. 2013;13:133. doi: 10.1186/1471-2407-13-133.CrossRefPubMedPubMedCentralGoogle Scholar